Cargando…
A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
BACKGROUND: The clinical outcomes of elderly patients with EGFR-mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib have not been sufficiently evaluated. This study aimed to assess the efficacy and safety of osimertinib in elderly chemotherapy-naive patients with NSCLC harbor...
Autores principales: | Igawa, Satoshi, Kasajima, Masashi, Ono, Taihei, Ozawa, Takahiro, Kakegawa, Mikiko, Kusuhara, Seiichiro, Sato, Takashi, Nakahara, Yoshiro, Fukui, Tomoya, Yokoba, Masanori, Kubota, Masaru, Mitsufuji, Hisashi, Sasaki, Jiichiro, Naoki, Katsuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612658/ https://www.ncbi.nlm.nih.gov/pubmed/34849025 http://dx.doi.org/10.2147/CMAR.S339891 |
Ejemplares similares
-
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019) -
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
por: Ono, Taihei, et al.
Publicado: (2019) -
Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018) -
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020) -
Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2020)